Rapamycin (Sirolimus) Real-World Evidence: Registries, RWE, and What the Data Actually Show

What Is Rapamycin (Sirolimus) and Why Does Real-World Evidence Matter?

Rapamycin is a macrolide compound originally isolated from Streptomyces hygroscopicus bacteria found in soil samples from Easter Island (Rapa Nui) in 1972. The FDA approved sirolimus (brand name Rapamune) in September 1999 for prophylaxis of organ rejection in renal transplant patients. Its use in healthy adults for longevity purposes is off-label and investigational.

Real-world evidence matters here for a specific reason: randomized controlled trials of longevity interventions take decades to power for hard endpoints like all-cause mortality. Registry data and observational cohorts can generate signal about intermediate endpoints, immune aging, self-reported healthspan, biomarker trajectories, far faster. The PEARL study is the largest prospective registry of this kind published to date.

Why Clinicians and Patients Are Paying Attention

A 2023 survey published in Aging Cell estimated that thousands of physicians and non-physicians were already self-administering rapamycin for anti-aging purposes before any prospective registry data existed [1]. That gap between practice and evidence is exactly what PEARL was designed to close.

Off-label prescribing at this scale carries genuine risk. Dose selection, monitoring intervals, and drug interactions vary widely across community practitioners, creating heterogeneous exposure profiles that registries can help characterize.

How Does Rapamycin (Sirolimus) Work? The mTOR Mechanism

Sirolimus works by binding intracellularly to the protein FKBP12 (FK506-binding protein 12). The sirolimus-FKBP12 complex then binds and allosterically inhibits mTORC1 (mechanistic target of rapamycin complex 1), a serine/threonine kinase that acts as a central nutrient and growth sensor in virtually every mammalian cell [2].

mTORC1 vs. MTORC2: Why the Distinction Matters Clinically

MTORC1 and mTORC2 have distinct functions. MTORC1 promotes anabolic processes: protein synthesis via S6K1 phosphorylation, lipid synthesis, and suppression of autophagy. MTORC1 inhibition by rapamycin therefore activates autophagy (cellular "self-cleaning"), reduces protein synthesis, and shifts cells toward a more quiescent metabolic state [3].

MTORC2 regulates cell survival, cytoskeletal organization, and glucose metabolism via AKT phosphorylation. Acute rapamycin exposure at standard doses does not directly inhibit mTORC2. Chronic or high-dose exposure can disrupt mTORC2 indirectly, which may explain some metabolic side effects observed with the daily transplant dosing regimen [4].

The Autophagy-Aging Connection

Autophagy declines with age. That decline allows damaged organelles and misfolded proteins to accumulate, accelerating cellular senescence. Rapamycin's activation of autophagy through mTORC1 inhibition is the primary mechanistic rationale for its longevity hypothesis. In a 2009 Nature report from the NIA Interventions Testing Program (ITP), late-life rapamycin administration (beginning at 600 days of age) extended median lifespan by 14% in male mice and 11% in female mice across three independent sites [5].

A subsequent ITP experiment beginning rapamycin at 9 months of age produced a 9% extension in males and 14% in females, with improved cardiac function and reduced cancer incidence as secondary findings [6].

Dosing Considerations: Daily vs. Weekly

The transplant label specifies 2 to 5 mg daily with target trough serum concentrations of 4 to 12 ng/mL (or up to 20 ng/mL in the first year post-transplant) [7]. Off-label longevity protocols almost universally use once-weekly dosing, typically 5, 6, or 10 mg, based on the hypothesis that intermittent mTORC1 inhibition achieves the autophagy pulse while limiting mTORC2 disruption and metabolic side effects.

No head-to-head pharmacodynamic comparison of daily versus weekly dosing in healthy adults has been published as a completed RCT as of this writing.

The PEARL Registry: What Real-World Evidence Actually Shows

PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is a prospective observational registry published in Aging Cell in 2024 (PMID 38497284) [8]. It is the most rigorous real-world dataset on rapamycin use in healthy aging adults to date.

Study Design and Population

PEARL enrolled 333 community-dwelling adults (mean age 61.2 years; 54% male) who were already taking or planning to take rapamycin for longevity purposes. This was not a randomized trial. Enrollment was open to self-selected participants, which introduces selection bias toward health-conscious individuals, a limitation the authors explicitly acknowledged.

Participants completed standardized questionnaires at baseline, 3 months, and 6 months covering self-reported health, energy, cognitive function, and immune-related symptoms. A subset provided blood samples for immune phenotyping.

Primary Findings at 6 Months

At 6 months, 76.1% of PEARL participants reported their overall health as improved or stable compared with baseline [8]. That figure includes:

• 47.3% reporting health as "improved"
• 28.8% reporting health as "stable"
• 23.9% reporting health as "worse" or "much worse"

Self-reported energy and cognitive function showed similar patterns, with roughly 55 to 60% of participants noting improvement or no change in each domain.

The immune phenotyping subsample showed a reduction in the CD4:CD8 T-cell ratio, a marker that typically inverts with age, in participants on rapamycin compared with non-users, though the sample size for this analysis was small (N=48) [8].

Dose Distribution in PEARL

The modal dose in PEARL was 6 mg once weekly, used by approximately 38% of participants. Another 29% used 5 mg weekly, and 18% used 10 mg weekly. Only 7% used any form of daily dosing, highlighting how far off-label practice has diverged from the transplant label [8].

Limitations the Authors Named

The PEARL authors explicitly stated that the registry "cannot establish causality" and that self-report bias "may overestimate benefit in a population self-selected for interest in the intervention." Blood-based aging biomarkers such as epigenetic clocks were not collected systematically, and no control arm existed.

Other Real-World Datasets: Transplant Registries and Observational Cohorts

SRTR and Transplant Registry Insights

The Scientific Registry of Transplant Recipients (SRTR) contains outcome data on tens of thousands of sirolimus-treated renal transplant patients. Analyses of SRTR data published in the American Journal of Transplantation have documented that sirolimus-based regimens are associated with lower rates of post-transplant malignancy compared with calcineurin inhibitor-based regimens, particularly non-melanoma skin cancers [9].

That anti-neoplastic signal in transplant patients is mechanistically coherent, mTORC1 promotes tumor cell proliferation, and its inhibition may reduce cancer risk. Whether this translates to a longevity benefit in healthy adults is an open question that PEARL cannot answer.

The TRIIM and TRIIM-X Trials

The TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial (N=9, published in Aging Cell 2019) was a small proof-of-concept study combining recombinant human growth hormone, DHEA, and metformin. Although rapamycin was not the intervention, TRIIM established proof-of-concept that immune and epigenetic aging may be reversible in older adults, framing the biological rationale that subsequent rapamycin registries built on [10].

TRIIM-X (N=25) expanded the cohort but again did not include rapamycin. These trials are cited here because they established the DNAm clock methodology (Horvath clock, PhenoAge, GrimAge) that PEARL and other rapamycin registries are beginning to incorporate [10].

OPARYL and European Observational Data

The OPARYL registry, coordinated through centers in Spain and France, tracks outcomes in sirolimus-converted renal transplant recipients over 5-year follow-up. An interim report presented at the European Renal Association Congress (2023) noted preserved eGFR and reduced cardiovascular events in patients converted from tacrolimus to sirolimus, though this is a transplant population, not a healthy-aging cohort.

Safety Signals Across Real-World Settings

Most Commonly Reported Adverse Effects

Across PEARL and published case series of off-label rapamycin use, the most commonly reported adverse effects at weekly doses of 5 to 10 mg are:

• Aphthous mouth sores (stomatitis): reported by approximately 20 to 30% of users in PEARL
• Fatigue or myalgia: 15 to 20%
• Acneiform rash: 8 to 12%
• Hyperlipidemia: well-documented at transplant doses; less systematically tracked in weekly off-label cohorts

The FDA label for sirolimus carries warnings for impaired wound healing, immunosuppression-related infections, and hyperlipidemia [7]. These warnings were established at daily transplant doses and may not apply at the same magnitude to weekly 5 to 10 mg dosing, but no powered safety trial in healthy adults has confirmed this.

Drug Interactions Worth Noting

Sirolimus is a CYP3A4 and P-glycoprotein substrate. Co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) can raise sirolimus blood levels several-fold [7]. Strong CYP3A4 inducers (rifampin, carbamazepine) can reduce levels significantly.

The FDA label explicitly states: "Avoid concomitant use of Rapamune with strong inhibitors or inducers of CYP3A4 and P-gp." [7] Clinicians prescribing off-label for longevity should obtain a full medication and supplement list before initiating.

The Glucose Metabolism Question

MTORC1 inhibition impairs insulin signaling downstream via IRS-1 phosphorylation, which can raise fasting glucose. Published data from the MESA cohort and other large observational datasets have documented a 20 to 30% increase in new-onset diabetes risk with chronic sirolimus use in transplant patients [11].

At weekly off-label dosing, the glucose effect appears attenuated based on PEARL self-report data, but no study has systematically measured fasting insulin or HOMA-IR in a controlled comparison of weekly vs. Daily dosing.

Ongoing Trials and What Evidence Is Still Missing

PEARL Phase 2 and Biomarker Extension

The PEARL investigators stated in their 2024 paper that a phase 2 extension collecting epigenetic clock data and standardized laboratory panels is in development. No completion date had been registered at ClinicalTrials.gov as of July 2025.

AFFIRM-WHIM and Immune Aging

The AFFIRM-WHIM trial (NCT04711486) tested rapalogues (RTB101, a selective TORC1 inhibitor) in older adults for immune function. Results showed a 30.6% reduction in confirmed respiratory illnesses at 16 weeks vs. Placebo in adults age 65 and older [12]. This is not rapamycin itself, but it is the closest RCT data for mTOR inhibition and immune aging in humans.

What the Evidence Gap Looks Like

No RCT has enrolled healthy adults, randomized them to weekly rapamycin vs. Placebo, and followed them for a pre-specified hard endpoint like all-cause mortality, hospitalization, or validated biological age. That trial would need thousands of participants and follow-up measured in years, not months. The PEARL registry fills some of that gap with real-world intermediate endpoints, but a causal inference cannot be drawn from its design.

The 2023 American Academy of Anti-Aging Medicine (A4M) conference position statement noted that "evidence for rapamycin in healthy human aging remains at the level of mechanistic plausibility and registry-grade observational data, not RCT-grade causal inference", a distinction that should inform informed consent conversations.

Monitoring Protocol for Off-Label Rapamycin Use

Clinicians who choose to prescribe sirolimus off-label for longevity purposes operate outside FDA-approved indications. The following monitoring framework reflects what is described across published case series and the PEARL registry protocol, not an FDA-endorsed standard of care.

Baseline Labs

Before initiating, obtain:

• Complete metabolic panel (fasting glucose, creatinine, liver enzymes)
• Fasting lipid panel
• CBC with differential
• Sirolimus trough level (if switching from daily dosing)
• Baseline blood pressure measurement

Ongoing Monitoring

At 4 to 6 weeks after initiation and every 3 to 6 months thereafter:

• Fasting lipid panel (LDL elevation is the most common lab abnormality)
• Fasting glucose or HbA1c
• CBC (monitor for anemia and thrombocytopenia at higher doses)
• Sirolimus trough 24 hours after the weekly dose, if dose-titrating

The FDA label states target troughs of 4 to 12 ng/mL for transplant patients [7]. Off-label weekly dosing often produces troughs below 4 ng/mL due to the intermittent schedule, and no validated therapeutic window has been established for the longevity indication.

Dose Titration Approach

Most published off-label protocols begin at 1 to 2 mg weekly and titrate upward over 4 to 8 weeks based on tolerability and trough levels. The PEARL modal dose of 6 mg weekly was not assigned by protocol, it reflects organic convergence among self-experimenting users, a methodological limitation worth acknowledging.

Who Is Currently Prescribing Rapamycin Off-Label and Why

A 2023 survey-based study published in Aging Cell (separate from the PEARL registry publication) found that among 1,414 respondents self-reporting rapamycin use for longevity: 78% were obtaining prescriptions from physicians, 14% from online telehealth services, and 8% from other sources including international pharmacies [1]. The physician prescribers included internists, longevity-focused practitioners, and a smaller proportion of endocrinologists and geriatricians.

The motivations reported most commonly were "extending healthspan" (82%), "immune rejuvenation" (67%), and "reducing cancer risk" (54%). These motivations are mechanistically coherent given rapamycin's known biology, but they have not been validated as clinical endpoints in prospective trials of healthy adults.

Rapamycin Versus Other mTOR Pathway Interventions

Metformin activates AMPK, which indirectly inhibits mTORC1, a partially overlapping mechanism. The TAME (Targeting Aging with Metformin) trial (NCT03077659) is currently enrolling 3,000 adults aged 65 to 79 across 14 US sites to test metformin 1,500 mg/day for composite aging endpoints with an estimated completion in 2027 [13]. TAME is the closest analogue to a powered longevity RCT and will provide a methodological template for future rapamycin trials.

Everolimus (RAD001), a rapamycin analogue, was tested in the OPERA trial at 0.5 mg/day or 5 mg/week in elderly adults for immune function. The 5 mg/week arm showed a 20% reduction in infection risk at 6 weeks, an effect that did not reach statistical significance but directionally supported the immune rejuvenation hypothesis [14].

Caloric restriction mimetics including NMN, resveratrol, and fisetin also target overlapping longevity pathways but act upstream of mTOR at NAD+ metabolism or SIRT1, not at mTORC1 directly. They are not substitutes for sirolimus in terms of mechanism.